Specialty drug access in Iraq: the KIMADIA / MOH named-patient pathway

Last reviewed 2026-05-18 by Reserve Meds clinical and regulatory team.

Quick orientation for Iraq

The Republic of Iraq operates the KIMADIA / Iraqi MOH named-patient import authorisation. The pathway is administered by the Iraqi State Company for Marketing Drugs and Medical Appliances (KIMADIA) under the Ministry of Health, allows an Iraqi-licensed physician at a registered tertiary facility to import an unregistered or unstocked FDA-labelled medicine for a specific named patient, and runs on 21 to 45 business days routine; 8 to 14 weeks for complex first-import (conflict-affected supply chain variability). Cost in IQD trading at approximately 1,310 IQD to 1 USD at the official rate, with specialty medicines typically priced in US dollars at the private hospital pharmacy counter, with annual drug cost for an oncology biologic typically in the USD 32,000 to USD 240,000 band at US WAC equivalents.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Iraqi patients face an access gap

The Republic of Iraq maintains a structured pharmaceutical regulatory environment. The local market registers and stocks an extensive core formulary across cardiology, endocrinology, antibiotics, and oncology, but four converging gaps drive cross-border named-patient demand.

First, indication lag. Specialty oncology, immunology, and rare-disease products approved at the US FDA in the past 24 to 36 months frequently lag local registration. An Iraqi oncologist with an FDA-label-fit case may face a 12 to 36 month delay before the drug arrives through routine commercial channels. Second, presentation gaps. The exact strength, weight-banded pediatric dose, or pen format the prescriber needs may be missing even when the molecule is on the local register. Third, payer denial. out-of-pocket cash (frequently USD) payment, supplemented by the MOH public hospital schemes for citizens, limited employer-paid plans through AAIB Insurance, Iraq Insurance Company, and Gulf Insurance Group Iraq, and the Iraqi Red Crescent compassionate support fund for specified rare-disease cases each assess specialty therapies case by case; step-therapy or formulary rules often produce denials even when the drug is locally registered. Fourth, continuity of supply. Iraqi patients stabilised on a US-sourced regimen during US-based care or family visits sometimes need to continue that exact presentation rather than switch to a different local formulation.

In each pattern, the KIMADIA / Iraqi MOH named-patient import authorisation is the legal mechanism that connects an Iraqi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient.

The regulator: the Iraqi State Company for Marketing Drugs and Medical Appliances (KIMADIA) under the Ministry of Health

The Iraqi State Company for Marketing Drugs and Medical Appliances (KIMADIA) under the Ministry of Health, commonly abbreviated as KIMADIA / MOH, is the Iraq national authority responsible for the registration, licensing, and surveillance of human medicinal products. The agency operates alongside the the Iraqi Medical Association and the MOH Department of Drug Registration; the combination of professional licensing (physician and pharmacy) with product licensing (medicine and manufacturer) defines the legal envelope within which the KIMADIA / Iraqi MOH named-patient import authorisation operates.

The agency publishes its current regulatory guidance on its public portal. Reserve Meds maintains a reading list of the current circulars and acts that govern personal-import authorisation; the regulator's guidance is the controlling source. Reserve Meds' role is to translate the documentation expectations into an applicant-ready packet, not to act as the regulator.

The named-patient route exists precisely because no regulator can register every FDA-approved indication, presentation, and dose-band the moment the FDA approves it. The mechanism is a principled exception, not a workaround. Reserve Meds operates exclusively within the principled-exception envelope.

The KIMADIA / MOH named-patient pathway in detail

The pathway for an Iraqi-licensed physician to obtain a medicine that is not registered or not stocked locally is the named-patient import authorisation administered jointly by the Iraqi State Company for Marketing Drugs and Medical Appliances (KIMADIA) and the Ministry of Health Department of Drug Registration, which allows a treating physician at a registered tertiary facility (typically within the Baghdad, Basra, or Erbil Medical City networks, or a licensed private hospital) to apply for the import of an unregistered medicine for a specific named patient where the medicine is approved by a recognised reference authority and no clinically equivalent locally registered alternative is suitable; the Kurdistan Region of Iraq operates a parallel authorisation route through the KRG Ministry of Health. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable.

A complete application typically includes: (1) a clinical justification letter from the treating physician naming the diagnosis, severity, prior therapies, why this specific drug, and why the locally stocked option is not suitable; (2) the treating physician's Iraqi medical license verification via the Iraqi Medical Association and the MOH Department of Drug Registration; (3) an anonymised patient identifier where KIMADIA / MOH submission rules allow; (4) full product details including brand name, generic name, manufacturer, strength, dosage form, pack size, requested quantity, and intended treatment duration; (5) the destination dispensing facility name, license number, and pharmacy in charge; (6) a chain-of-custody plan from US manufacturer through importer to dispensing pharmacy.

Approval timelines for routine cases run 21 to 45 business days from a complete filing. Complex first-import cases (rare indication, larger quantities, first pediatric or weight-banded format) extend to 8 to 14 weeks. KIMADIA / MOH retains discretion on timing and we never promise specific durations.

The Iraq payer landscape

Iraq health financing combines public coverage and private insurance in proportions that vary by socioeconomic stratum and by treatment setting. The major payers we see in named-patient imports are out-of-pocket cash (frequently USD) payment, supplemented by the MOH public hospital schemes for citizens, limited employer-paid plans through AAIB Insurance, Iraq Insurance Company, and Gulf Insurance Group Iraq, and the Iraqi Red Crescent compassionate support fund for specified rare-disease cases.

Public coverage typically reimburses essential-medicine list items at the dispensing pharmacy with co-payment, but specialty oncology biologics and gene therapies frequently fall outside the public formulary. Private insurance plans assess named-patient imports against individual policy terms; pre-authorisation is the rule, not the exception, and the documentation set Reserve Meds prepares is designed to support the pre-authorisation submission to the insurer as well as the KIMADIA / MOH application itself.

For cash-pay families (the majority of cross-border specialty cases globally), Iraq pricing is informed by US WAC equivalents plus international logistics. The annual cost band for an oncology biologic at FDA-labelled adult dosing typically falls in the USD 32,000 to USD 240,000 range at US WAC equivalents in the Iraq market, with the dispensing hospital adding its infusion or administration fee separately. Reserve Meds itemises the concierge fee on every firm quote; we do not bundle drug cost into a single line.

Top hospitals handling named-patient imports in Iraq

A small group of tertiary and major private hospitals in Iraq handle named-patient imports as established workflow. These centres maintain in-house import-pharmacy infrastructure, physicians experienced with the KIMADIA / MOH application set, and validated cold-chain storage (2 to 8 degrees Celsius for biologics, ultra-cold or specialised handling where the FDA label requires it). The most active centres are Baghdad Medical City Complex in Baghdad, Basra Teaching Hospital and the Basra Oncology Center, Hiwa Cancer Hospital in Sulaymaniyah, Erbil Oncology Hospital and Rizgary Teaching Hospital in Erbil, and Al Amal National Hospital for Cancer Management in Baghdad.

For physicians at smaller hospitals without internal import infrastructure, the standard pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the KIMADIA / MOH application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation that Reserve Meds prepares and the importer co-signs.

Common indications driving named-patient demand in Iraq

Across cases we coordinate or anticipate coordinating in the Iraq market, four therapeutic areas dominate named-patient demand. Oncology accounts for the majority of cross-border specialty cases: PD-1 and PD-L1 checkpoint inhibitors (Keytruda, Opdivo, Tevimbra), antibody-drug conjugates (Tivdak, Datroway), tyrosine kinase inhibitors (Lazcluze, Ibtrozi, Ensacove), bispecific T-cell engagers (Talvey, Tecvayli, Tepkinly, Imdelltra), and PARP inhibitors (Zejula). Rare-disease gene therapies form a fast-growing second tier: hemophilia gene therapy (Roctavian, Hemgenix), sickle cell disease (Lyfgenia), metachromatic leukodystrophy (Lenmeldy), and recessive dystrophic epidermolysis bullosa (Zevaskyn).

The third group is immunology and dermatology biologics where Iraq local label or stocking lags the US FDA approval window: newer IL-13 and IL-17 inhibitors and JAK inhibitors at expanded indications. The fourth group is pulmonary hypertension, cardiology, and metabolic-disease specialty products where small-molecule and biologic options have crossed FDA approval but not local registration: Winrevair, Wainua, Qfitlia, Alhemo, Vyondys 53. Reserve Meds maintains a per-drug, per-country matrix detailing the named-patient pathway for each of these molecules in Iraq.

Quality, chain-of-custody, and DSCSA compliance for Iraq cases

Every medicine Reserve Meds coordinates is sourced from the US manufacturer through a Drug Supply Chain Security Act (DSCSA)-compliant specialty channel. The DSCSA mandates serialised tracing of every saleable unit from manufacturer through wholesale distributor to dispensing pharmacy in the United States. For cross-border named-patient supply to Iraq, we maintain the DSCSA chain to the point of US export and preserve the documented lineage in the chain-of-custody record that accompanies the international shipment. This is the operational answer to the counterfeit concern that haunts the global specialty market: the Iraq patient receives a unit whose lineage can be traced back to the US manufacturer with full serialisation data.

Cold-chain integrity is the second pillar. Most specialty biologics (monoclonal antibodies, antibody-drug conjugates, fusion proteins, gene therapies) require continuous 2 to 8 degrees Celsius storage from manufacturer through dispensing pharmacy. Our cold-chain protocol uses qualified passive or active containers, continuous temperature data loggers, and validated lane planning with stability data overlaid on the expected transit time. Ultra-cold (-20 degrees or below) products require dry-ice or phase-change-material containers with explicit lane qualification. The dispensing pharmacy in Iraq confirms storage compliance on receipt; the cold chain is broken only at the dispensing pharmacy under documented control. Excursion handling follows the manufacturer's labelled stability runway: a documented out-of-range excursion triggers an immediate medical-affairs review and, where required, product replacement.

Cost and currency picture in Iraq

IQD is trading at approximately 1,310 IQD to 1 USD at the official rate, with specialty medicines typically priced in US dollars at the private hospital pharmacy counter. For a typical oncology biologic at FDA-labelled adult dosing, the US WAC-equivalent annual cost in the Iraq market falls between USD 32,000 and USD 240,000. International logistics adds USD 500 to USD 1800 per shipment depending on destination city, urgency, and cold-chain requirements. KIMADIA / MOH permit fees are nominal relative to drug cost.

Reserve Meds builds the firm quote against current US manufacturer list pricing (Pfizer, Merck, Roche, BMS, Lilly, Novartis, AstraZeneca, AbbVie, Regeneron, and others as applicable to the prescribed drug) and itemises each line: drug cost, international logistics, KIMADIA / MOH permit and customs fees, and the Reserve Meds concierge fee. Manufacturer copay cards and patient-assistance programmes available to US patients do not extend internationally; cross-border patients pay cash or rely on local payer coverage.

We do not act as a price negotiator with the US manufacturer. We do act as a transparent line-item intermediary: every quote shows the manufacturer-pass-through drug cost as a separate line so the patient and physician can see exactly what they are paying for. That transparency is central to the trust posture we maintain with Iraq families and prescribers.

Typical end-to-end timeline in Iraq

KIMADIA / MOH routine processing is typically 21 to 45 business days from a complete filing. International logistics adds 2 to 5 additional days depending on whether the presentation is ambient or cold-chain, the dispensing city, and customs clearance. End-to-end, most routine adult cases complete within 3 to 6 weeks from first complete documentation. Complex first-import cases run to 8 to 14 weeks.

The binding step is rarely the KIMADIA / MOH review itself when the application is filed clean. It is usually documentation completeness on the prescriber's side or, for cold-chain biologics, the dispensing facility's storage and monitoring confirmation. The intake is where Reserve Meds locks the case-team contact, gathers documents in parallel, and starts the US sourcing clock so that approval and product land in the same week rather than serially.

What your physician needs to provide

For an Iraqi-licensed specialist filing through KIMADIA / MOH, the clinical justification letter is the cornerstone of the application. The letter documents the patient's confirmed diagnosis, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate), prior therapy history including first-line options tried, and a clinical rationale for the prescribed medicine given its FDA-labelled mechanism.

The letter specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan references any baseline laboratory or imaging requirements specific to the medicine, planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Iraqi license number (verifiable via the Iraqi Medical Association and the MOH Department of Drug Registration), the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record Reserve Meds shares with the importer.

Where Reserve Meds fits in Iraq cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace KIMADIA / MOH, and we do not replace your dispensing pharmacy. For Iraq cases specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Iraq, and assign a single named coordinator through the case.

Operationally, a typical Iraq case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule. The regulatory track is the KIMADIA / MOH application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Reserve Meds is not an insurer, not a benefits administrator, and not a substitute for legal advice in Iraq. Regulatory posture on this page is informational; case-specific questions route to retained outside counsel.

Next step for Iraq patients

If your Iraqi physician has prescribed a US-sourced specialty medicine through the KIMADIA / Iraqi MOH named-patient import authorisation, the next step is a short intake request. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to your physician. The kit includes the clinical justification letter template, the KIMADIA / MOH application checklist, the chain-of-custody attestation form, and the cold-chain monitoring receipt log. Your physician fills the clinical sections; we file the regulatory sections with the importer. Patient and physician track the case in real time through the Reserve Meds patient portal.

Start your caseWhatsApp

Reserved for you.